Bulletin

Endo outbids Valeant with $15.7bn Salix offer as drug sector heats up

Pharmacy

Ireland-based pharmaceuticals group Endo has moved to gatecrash Valeant's takeover bid for US gastrointestinal drugmaker Salix by making its own $15.7bn approach, compared with Valeant's $14.5bn offer. The activity is a further sign of the frenetic pace of deal making in the drugs industry, which last week saw AbbVie win a three-way fight for Pharmacyclics, a biotech company that makes a single cancer drug, with a $21bn offer. Almost $70bn of deals have been unveiled in pharma and biotech this year, according to Thomson Reuters, double the level of activity at the same point in 2014. Since the start of 2014, the global healthcare sector has seen $475bn of deals. Quebec-based Valeant had said it would use its non-US domicile and ultra-low tax rate to extract value from the deal, with the combined company enjoying a tax rate of 5%, compared to around 30% for Salix. Endo would be able to make similar savings after reincorporating in Ireland last year.

 

Note: News bulletin content has been provided by a third-party and is not the opinion of Santander.

Other Articles

This International Women’s Day, our analysis reveals a continuing untapped potential and huge opportunity when it comes to women in…

London

London-based ACT Clean has secured private investor backing for a £10.2 million management buyout.

Bulletin
Spain

Santander takes 12 UK food and drink manufacturers to Spain on one of our successful trade missions. Adam Payne in the international team…

London

London-based ACT Clean has secured private investor backing for a £10.2 million management buyout.

Bulletin

This International Women’s Day, our analysis reveals a continuing untapped potential and huge opportunity when it comes to women in…

Getting a taste for Spain!

Santander takes 12 UK food and drink manufacturers to Spain on one of our Trade Missions. Alicia Ferrero Vega in the International team…

Bulletin

Where Next?